Navigation Links
Data Presented at the American Psychiatric Association (APA) Annual Meeting Demonstrate Iloperidone's Efficacy and Safety, With Low Rates of Movement and Metabolic Adverse Events
Date:5/6/2008

treatment for each patient," said Paolo Baroldi, M.D., Ph.D., Chief Medical Officer, Vanda Pharmaceuticals Inc.

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, iloperidone, is under clinical investigation for the treatment of schizophrenia, but has not been approved by any regulatory authority. The FDA accepted Vanda's iloperidone New Drug Application (NDA) for filing in November 2007 and Vanda expects a decision from the FDA on or about July 27, 2008. Vanda's second product candidate, tasimelteon (VEC-162), is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for chronic primary insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

Cautionary Note Regarding Forward-Looking Statements

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward- looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure o
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Treprostinil Data to be Presented at Annual Meeting of the American Thoracic Society
2. New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting
3. Phase 3 Data Regarding Anti-RSV Antibody To Be Presented at Pediatric Academic Societies (PAS) Annual Meeting
4. Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL
5. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
7. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
8. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
9. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
10. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
11. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2008)... III Study Shows Positive Results with X-ray ...May 9 /- Roche today announced one-ye...wing that ACTEMRA(TM),(tocilizumab) can significan...ints in patients with rheumatoid arthritis (RA), a...ent. The study also demonstrated that ACTEMRA,redu...
(Date:5/8/2008)...ire-FirstCall/ -- DATATRAK International, Inc.,(Na...ocused on global,eClinical solutions for the clini...results for the first quarter of 2008., For the t...d,approximately 41% to $2,088,000 and the Company ...r share on both a basic and diluted basis. These,r...
(Date:5/8/2008).../ -- The Cancer Research Alliance, an,organization...s, is asking,303 million Americans to exercise the...arch efforts this Mother,s Day through Father,s Da...ne(TM)" has two key goals:,to activate Americans e...joining together to exercise their collective powe...
(Date:5/8/2008)...ort potential of asenapine in the treatment of ..., WASHINGTON, May 8 /- Sch...nced that an overview of asenapine clinical trials...st Annual Meeting of the,American Psychiatric Asso...e studies, involving patients with bipolar I disor...
Breaking Medicine Technology:New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 2New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 3New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 4New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients 5DATATRAK International Reports First Quarter Results for 2008 2DATATRAK International Reports First Quarter Results for 2008 3DATATRAK International Reports First Quarter Results for 2008 4DATATRAK International Reports First Quarter Results for 2008 5DATATRAK International Reports First Quarter Results for 2008 6DATATRAK International Reports First Quarter Results for 2008 7World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7Five Hospitals to Share Patient Data 3A ICW Connects Regional Medical Centers and University Facility 6914 1Five Hospitals to Share Patient Data 3A ICW Connects Regional Medical Centers and University Facility 6914 2Five Hospitals to Share Patient Data 3A ICW Connects Regional Medical Centers and University Facility 6914 3TriWest Sponsors Lt Dan Band Performance for Families of Fallen Service Members at Snowball Express Gala 6910 1TriWest Sponsors Lt Dan Band Performance for Families of Fallen Service Members at Snowball Express Gala 6910 2CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference 1947 1CuraGen to Present at the 19th Annual Piper Jaffray Health Care Conference 1947 2CSL Behring Reaches Primary Endpoint in Clinical Study of C1 INH for Treatment of Hereditary Angioedema 914 1CSL Behring Reaches Primary Endpoint in Clinical Study of C1 INH for Treatment of Hereditary Angioedema 914 2CSL Behring Reaches Primary Endpoint in Clinical Study of C1 INH for Treatment of Hereditary Angioedema 914 3CSL Behring Reaches Primary Endpoint in Clinical Study of C1 INH for Treatment of Hereditary Angioedema 914 4
(Date:5/12/2008)...2 /PRNewswire-FirstCall/ - The Westaim Corporation...March 31, 2008, it,recorded a net loss of $6.9 mil...lion. In the same quarter last year, the company r... share, on revenues of $6.1 million., Income from...arter,compared to $1.9 million in the same period ...
(Date:5/12/2008)...., May 12 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT,...r the "Corporation") announced,that the Toronto St...ing it,is reviewing the eligibility for continued ...art under sections 709 and 710(a) of the TSX Compa...nancial condition and,operating results, more spec...
(Date:5/12/2008)... 12 /PRNewswire-FirstCall/ -- Allied Healthcare Pr...its net income for the third,quarter ending March ... or,4 cents per share, to about $100,000 in the cu...e third quarter increased by about $240,000 compar..., higher material and labor costs,this fiscal year...
(Date:5/12/2008)... May 12 /Xinhua-PRNewswire-FirstCall/ -- China Yin...) ("China Yingxia" or "the,Company"), a leading pr...e,development, manufacture and distribution of org...ersonal care products in the People,s Republic,of ...onference call,Friday, May 16, 2008, at 10:00 a.m...
Breaking Medicine News(10 mins):Health News:Westaim announces 2008 first quarter results 2Health News:Westaim announces 2008 first quarter results 3Health News:WorldHeart Notified of TSX Delisting Review 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 2Health News:Allied Healthcare Net Falls on Manufacturing Delays 3Health News:Allied Healthcare Net Falls on Manufacturing Delays 4Health News:Allied Healthcare Net Falls on Manufacturing Delays 5Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2
...ation system that can perform a variety of tests o...icket captain Dilip Vengsarkar here Tuesday//. Pri...otherapists to accurately measure the performance,...els of sportspersons. "The heavy emphasis on Ind...
...ded for consumption without a break is threatening...ve pill//. The pill, named Anya, manufactured by W...th Canada, which will enable women to give a merry...e in neither United States nor Canada, Anya is und...
...he first province in Canada to start accepting tra...failure//. The provincial agency in charge of org...guidelines that allowed accepting donation after c...ould potentially expand the potential donor pool b...
...Sainsbury's are negotiating details about running ...ie Oliver//, to promote the dying concept of famil.... This would mark a controversial departure for g...ts tie-up with a commercial brand. The health depa...
Other Medicine News:Health News:Ontario Addresses Shortage of Transplant Organs 2
The NIAGARA Thermal Retention System (TRS) maintains the temperature of prewarmed irrigation fluid continuously as it is delivered through the Corson®, Surgiflex® WAVE™, or Surgiflex D
...ace the eyeglasses in the EZ Meter and press the m...isplay the measurement results on its large color ... printout makes this the ideal instrument for use ...ion to being extremely easy-to-use, the EZ-200 is ...
Simple, Effective Laparoscopic Irrigation Pumps from the Market Leader
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump.
Medicine Products: